CA
NZ
UK
AU
IND
US
AMETEK, Inc.'s Q2 2026 earnings call revealed a record backlog of $4.11 billion, with approximately 80% expected to ship within 12 months. This milestone is a significant indicator of the company's growth prospects, particularly in the areas of AI, semiconductor fabs, and power plants. …
Arcosa, Inc. (NYSE: ACA) delivered second-quarter revenues of $658.7 million, marking a 2% increase from $647.5 million one year prior. This result falls short of expectations, with the consensus estimated at $1.20 for adjusted EPS, which came in at $1.13. Income from continuing operations …
This boost in revenue is indicative of the company's operational efficiency and market demand, driven partly by its recent acquisition of Micro Bird, which contributed $122.9 million to net sales for the quarter. The performance outpaced the consensus forecast, which expected earnings per share …
Zomedica Corp. (NYSE American: ZOMDF) delivered a remarkable second quarter, reporting $9.5 million in revenue, which marks a 37% year-over-year increase from the previous record of $7.0 million set in 2025. This impressive performance highlights the company's sustained growth trajectory, driven by a strong …
Solventum Corp (NYSE: SOLV) intends to separate its Health Information Systems business, anticipating significant value creation estimated at approximately $10 billion. This strategic move is part of a broader portfolio optimization initiative designed to reposition Solventum as a focused MedTech company, concentrating on its …
STERIS plc (NYSE: STE) announced a 7% revenue increase to $1.5 billion for the first quarter ended June 30, alongside diluted EPS up to $2.04. Adjusted EPS rose to $2.59, exceeding the $2.53 consensus estimate. This growth reflects solid performance in the healthcare segment, …
UroGen Pharma Ltd. reported $50.4 million in revenue from its leading drug, ZUSDURI, for the second quarter of 2026, a remarkable 73% increase compared to the first quarter. The impressive growth is attributed to a ramp-up in prescription uptake, reflecting the drug's expanding position …
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 earnings per share of $‑1.04, falling short of the $‑0.60 consensus estimate. Fanapt net product sales climbed 23% year‑over‑year to $36.0 million, while total prescriptions increased 31%. Management lifted full‑year revenue guidance to a $240‑$290 million range and …
This outcome starkly contrasts with the consensus estimate of $-0.60 per share, raising flags among investors concerned about the company's financial trajectory. Shares have, meanwhile, decreased 38.3% year-to-date, reflecting ongoing market challenges. Vanda’s market valuation now sits at approximately $307 million, with a 52-week …
The company's quarterly earnings per share (EPS) was significantly underwhelming, coming in at $-2.30 against a consensus estimate of $-1.79. Such financial outcomes highlight the pressures faced by Vaxcyte as it ramps up investment in its innovative vaccine pipeline while aiming for greater market …
Please wait processing your request...